Literature DB >> 25660949

The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.

Margarida Rei1, Daniel J Pennington2, Bruno Silva-Santos3.   

Abstract

Tumor-infiltrating lymphocytes are key mediators of tumor immune surveillance and are important prognostic indicators in cancer progression. Among the various lymphocyte subsets implicated in protection against cancer are γδ T lymphocytes, which can kill tumor cells and secrete potent antitumor cytokines. By contrast, recent reports have revealed an unexpected series of protumor functions of γδ T cells in mouse models and human patients. In particular, specific γδ T-cell subsets are capable of recruiting immunosuppressive myeloid populations, inhibiting antitumor responses, and enhancing angiogenesis, thus promoting cancer progression. A common mediator of such functions appears to be the cytokine IL17, whose pathogenic effects can override the antitumor immune response orchestrated by IFNγ. Here, we review these studies and discuss their implications for the manipulation of γδ T cells in cancer immunotherapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25660949     DOI: 10.1158/0008-5472.CAN-14-3228

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms.

Authors:  Wai H Lim; Steven J Chadban
Journal:  J Am Soc Nephrol       Date:  2015-11-12       Impact factor: 10.121

2.  Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays.

Authors:  Marie Tosolini; Frédéric Pont; Mary Poupot; François Vergez; Marie-Laure Nicolau-Travers; David Vermijlen; Jean-Emmanuel Sarry; Francesco Dieli; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

3.  IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.

Authors:  Lloyd Bod; Renée Lengagne; Ludovic Wrobel; Jan Philipp Ramspott; Masashi Kato; Marie-Françoise Avril; Flavia Castellano; Valérie Molinier-Frenkel; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

4.  Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.

Authors:  Jae W Lee; Chad A Komar; Fee Bengsch; Kathleen Graham; Gregory L Beatty
Journal:  Curr Protoc Pharmacol       Date:  2016-06-01

Review 5.  Challenges and opportunities of allogeneic donor-derived CAR T cells.

Authors:  Yinmeng Yang; Elad Jacoby; Terry J Fry
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

Review 6.  γδ T Cells: Unexpected Regulators of Cancer Development and Progression.

Authors:  Christopher Fleming; Samantha Morrissey; Yihua Cai; Jun Yan
Journal:  Trends Cancer       Date:  2017-07-17

7.  Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.

Authors:  T Hoeres; M Wilhelm; M Smetak; E Holzmann; G Schulze-Tanzil; J Birkmann
Journal:  Clin Exp Immunol       Date:  2018-01-04       Impact factor: 4.330

8.  The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome.

Authors:  Pauline Girard; Julie Charles; Camille Cluzel; Emmanuelle Degeorges; Olivier Manches; Joel Plumas; Florence De Fraipont; Marie-Therese Leccia; Stephane Mouret; Laurence Chaperot; Caroline Aspord
Journal:  Oncoimmunology       Date:  2019-04-17       Impact factor: 8.110

9.  Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.

Authors:  Teruki Shimizu; Mako Tomogane; Masatsugu Miyashita; Osamu Ukimura; Eishi Ashihara
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

10.  Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of γδ17 T cells in melanoma.

Authors:  Laetitia Douguet; Lloyd Bod; Renée Lengagne; Laura Labarthe; Masashi Kato; Marie-Françoise Avril; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2016-08-10       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.